Medical compositions for intravesical treatment of bladder cancer

Abstract

Anti-cancer coating compositions comprising 3-hydroxymethyl-5-aziridinyl-1-1-methyl-2-[1 H-indole-4,7-dione]propenol (E09) are disclosed. More specifically, the coating compositions comprise EO9 and a formulation vehicle. The formulation vehicle improves the solubility and stability of EO9. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.

1 . An anti-cancer formulation comprising: 
 an indolequinone having a pH within a range of approximately 9 and approximately 9.5, a refractive index within a range of approximately 1.393 to approximately 1.406, and a relative density of within a range of approximately 0.94 to approximately 0.95.    
   
   
       2 . The anti-cancer formulation of  claim 1  wherein the indolequinone is 3-hydroxymethyl-5-azirid inyl-1-1-methyl-2-[1H-indole4,7-d ione]propenol.  
   
   
       3 . The anti-cancer formulation of  claim 2  further comprising a coating composition.  
   
   
       4 . The anti-cancer formulation of  claim 3  wherein the coating composition is selected from the group consisting of propylene glycol, hydroxypropylcellulose, carboxymethylcellulose, chitosan hydrochloride, lectin, and polycarbophil.